Ellie Leick
Articles
Proceed With Caution: Transplants for Blood Cancer in the Era of COVID-19
April 20, 2020
Article
In light of the COVID-19 pandemic, transplant-eligible patients with cancer are undergoing careful assessment to determine whether they should proceed with the procedure or receive additional consolidation therapy to buy time, according to Naval G. Daver, MD.
Surgery a Mainstay in Melanoma as New Treatments Emerge
April 17, 2020
Article
Although the emergence of more targeted and immunotherapies continues to expand the melanoma treatment paradigm, surgery remains an important tool in the management of these patients, according to Omid Hamid, MD.
Racial Disparities Exist in Endometrial Cancer Care
March 28, 2020
Article
Retrospective results showed that African-American women with endometrial cancer are less likely to receive evidence-based care compared with white women—1 factor causing significant racial disparities in endometrial cancer care, explained senior study author Jason D. Wright, MD.
Biomarkers and Combo Therapy: What's Next in Prostate Cancer
March 12, 2020
Article
Biomarker-driven treatments continue to expand in prostate cancer, as research efforts explore responses across different subgroups, explained Petros Grivas MD, PhD.
More Work Needed to Determine Best Treatment for High-Risk Myeloma
February 29, 2020
Article
Autologous stem cell transplantation continues to have a significant role for patients with high-risk myeloma; however, research efforts continue to focus on novel induction, consolidation, and maintenance regimens, as well as the use of tandem transplant, explained Andrew Branagan, MD.
Biomarkers Predict Osteosarcoma Treatment Response
February 02, 2020
Article
The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.
Updated Data Unveiled With Emerging Treatments in Myeloma
January 25, 2020
Article
Updated data on several emerging treatment modalities were presented at the 2019 ASH Annual Meeting in multiple myeloma, including CAR T-cell therapy, antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and a novel selinexor (Xpovio) combination, explained Sandy W. Wong, MD.
The HER2+ Breast Cancer Landscape Continues to Change
January 14, 2020
Article
Research presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) had a significant effect on the standard of care for patients with HER2-positive metastatic breast cancer, explained Erika P. Hamilton, MD.
Immunotherapy Combos Are Now Standard of Care for Advanced RCC
January 13, 2020
Article
The standard of care for treatment-naïve patients with advanced renal cell carcinoma (RCC) has shifted from a single-agent VEGF TKI to a checkpoint inhibitor plus either a VEGF TKI or a CTLA-4 inhibitor, explained David F. McDermott, MD.
New Regimens Improve Kidney Cancer Outcomes
January 09, 2020
Article
The approval of several TKIs and combination regimens has led to more treatment options for patients with renal cell carcinoma (RCC), with a heavier focus on individualized approaches, explained Ajjai Shivaram Alva, MBBS.